MedicaSafe partners with Amneal on generic Suboxone monitoring

Press enter to search
Close search
Open Menu

MedicaSafe partners with Amneal on generic Suboxone monitoring

By Sandra Levy - 10/03/2019

MedicaSafe is partnering with Amneal to provide Amneal’s generic Suboxone (buprenorphine and naloxone) as part of MedicaSafe’s data-generating medication system. This partnership provides a system aimed to deliver real-time information about the patient’s medication access pattern, producing actionable information for clinicians treating opioid use disorder.

“The MedicaSafe system enables dose-by-dose tracking of medication access,” MedicaSafe CEO Matt Ervin said. “Our research with generic Suboxone indicates that providing clinicians with detailed data on medication access can allow them to adjust treatments in a targeted and timely manner.”

Amneal’s generic Suboxone will come pre-packaged in disposable, secure and tamper-evident MedicaSafe cartridges. A separate companion device, the MedicaSafe SmartKey, will be required to dispense an authorized dose from a cartridge. The SmartKey will then authenticate the user and consider factors such as the prescribed regimen and recent medication access before dispensing. Prescribers will be able to specify the dose access algorithm via a standard written prescription, while specialty pharmacies will handle setup and distribution.

The MedicaSafe SmartKey records each dispensation and transfers data to a cloud portal for prescriber review. Reports aim to highlight aberrant patterns for a single individual and across a patient population.

Prescribers can rule out tampering by asking patients to bring cartridges to each office visit. Dose dispensation data can be further corroborated by lab tests to confirm that doses were ingested. These approaches are consistent with current standard of care.

“We are happy to partner with the MedicaSafe team as they bring data-generating medication systems to market,” Amneal co-CEO Chirag Patel said.“Clinicians dealing with opioid misuse desire new treatment approaches, and we hope a complete system like this can help prescribers treat OUD and promote successful compliance.”

Related Topics